Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.90 USD
-0.09 (-4.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.93 +0.03 (1.58%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum C VGM
Earnings News For ESPR
-
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
-
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
-
Esperion Therapeutics: Q4 Earnings Snapshot
-
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
-
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
-
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?
-
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
-
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
-
Esperion Therapeutics: Q3 Earnings Snapshot
-
Esperion Reports Third Quarter 2023 Financial Results
-
Why Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?
-
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
-
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
-
Esperion Therapeutics: Q2 Earnings Snapshot
-
Esperion Reports Second Quarter 2023 Financial Results
-
Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?
-
Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up
-
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
-
Esperion Therapeutics: Q1 Earnings Snapshot
-
Esperion Reports First Quarter 2023 Financial Results
-
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?
-
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
-
Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates